Welcome to our dedicated page for Design Therapeutics news (Ticker: DSGN), a resource for investors and traders seeking the latest updates and insights on Design Therapeutics stock.
Design Therapeutics, Inc. reports news about its clinical-stage biotechnology business and its GeneTAC® platform for serious degenerative genetic diseases. The company develops gene targeted chimera small molecules designed to modulate expression of disease-causing genes, with programs that include DT-216P2 for Friedreich ataxia, DT-168 for Fuchs endothelial corneal dystrophy, DT-818 for myotonic dystrophy type 1, and a Huntington’s disease program.
Recurring updates cover financial results, cash resources for pipeline execution, clinical program progress, regulatory clearances, preclinical development, investor conference participation, and board or committee changes. Company announcements frequently connect portfolio milestones with the underlying GeneTAC approach and the therapeutic areas addressed by its genomic medicine programs.
Design Therapeutics, a biotechnology company focused on treatments for degenerative genetic disorders, announced that CEO João Siffert will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference. This event is scheduled for June 9, 2021, at 1:20 p.m. ET. A live webcast will be available on the company's investor website and archived for 60 days. Design Therapeutics specializes in GeneTAC™ small molecules aimed at targeting disease-causing genes, with their lead program focusing on Friedreich ataxia.
Design Therapeutics (Nasdaq: DSGN) announced the appointment of Heather Behanna, Ph.D., and Deepa Prasad to its board of directors, effective June 15, 2021. Behanna, a principal at SR One, brings extensive experience in biotechnology and rare disease therapies, while Prasad, managing director at WestRiver Group, has over 20 years in healthcare investment. These appointments aim to strengthen the company’s strategic direction as it transitions to a clinical-stage entity, particularly in its Friedreich ataxia program slated for clinical development in early 2022.
Design Therapeutics completed a successful $276 million IPO in March 2021 to advance its GeneTACTM programs for Friedreich Ataxia (FA) and Myotonic Dystrophy Type-1 (DM1). The company reported a net loss of $5.5 million for Q1 2021, up from a loss of $0.7 million in Q1 2020, with R&D expenses rising significantly. Design is on track to initiate a Phase 1 clinical trial for FA in H1 2022, following a productive pre-IND meeting with the FDA. As of March 31, 2021, the company had cash and equivalents totaling $411.3 million, a considerable increase due to IPO proceeds.
Design Therapeutics, Inc. (Nasdaq: DSGN) has successfully closed its initial public offering, selling 13.8 million shares at $20.00 each, including 1.8 million shares from underwriters' options. The total gross proceeds amount to approximately $276 million before expenses. The shares began trading on the Nasdaq Global Select Market on March 26, 2021. This funding aims to support Design's development of GeneTAC™ small molecules for treating serious degenerative disorders caused by inherited nucleotide repeat expansions.
Design Therapeutics has priced its initial public offering (IPO) at $20.00 per share, aiming to raise $240 million with 12 million shares being offered. The IPO will commence trading on the Nasdaq under the ticker symbol DSGN on March 26, 2021, and is expected to close on March 30, 2021. A 30-day option for underwriters to purchase an additional 1.8 million shares is also granted. Goldman Sachs, SVB Leerink, and Piper Sandler are managing the offering.